ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 256 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $980 | +0.3% | 27,496 | +30.6% | 0.00% | 0.0% |
| Q2 2023 | $977 | +23.4% | 21,048 | +6.7% | 0.00% | 0.0% |
| Q1 2023 | $792 | -33.7% | 19,729 | -23.1% | 0.00% | -33.3% |
| Q4 2022 | $1,195 | -99.7% | 25,660 | +162.2% | 0.00% | +200.0% |
| Q3 2022 | $404,000 | +90.6% | 9,787 | +175.5% | 0.00% | 0.0% |
| Q2 2022 | $212,000 | -20.9% | 3,553 | +2.0% | 0.00% | 0.0% |
| Q1 2022 | $268,000 | -13.8% | 3,484 | -6.1% | 0.00% | 0.0% |
| Q4 2021 | $311,000 | -5.8% | 3,710 | +1.9% | 0.00% | 0.0% |
| Q3 2021 | $330,000 | -4.9% | 3,641 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $347,000 | -22.5% | 3,641 | -8.3% | 0.00% | 0.0% |
| Q1 2021 | $448,000 | -13.5% | 3,969 | +5.6% | 0.00% | 0.0% |
| Q4 2020 | $518,000 | +67.6% | 3,759 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $309,000 | +5.5% | 3,759 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $293,000 | +74.4% | 3,759 | 0.0% | 0.00% | – |
| Q1 2020 | $168,000 | +5.7% | 3,759 | 0.0% | 0.00% | – |
| Q4 2019 | $159,000 | -64.3% | 3,759 | -46.6% | 0.00% | -100.0% |
| Q2 2019 | $446,000 | -1.8% | 7,036 | +7.0% | 0.00% | 0.0% |
| Q1 2019 | $454,000 | +102.7% | 6,576 | +23.1% | 0.00% | 0.0% |
| Q4 2018 | $224,000 | -45.2% | 5,344 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $409,000 | -0.5% | 5,344 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $411,000 | +29.2% | 5,344 | -14.1% | 0.00% | 0.0% |
| Q1 2018 | $318,000 | +10.4% | 6,219 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $288,000 | +29.1% | 6,219 | +50.3% | 0.00% | 0.0% |
| Q3 2017 | $223,000 | -13.2% | 4,139 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $257,000 | -8.2% | 4,139 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $280,000 | -4.1% | 4,139 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $292,000 | -50.2% | 4,139 | -50.0% | 0.00% | 0.0% |
| Q3 2016 | $586,000 | +190.1% | 8,278 | +100.0% | 0.00% | 0.0% |
| Q2 2016 | $202,000 | +24.7% | 4,139 | +62.0% | 0.00% | 0.0% |
| Q1 2016 | $162,000 | -43.6% | 2,555 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $287,000 | +16.2% | 2,555 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $247,000 | +34.2% | 2,555 | +41.9% | 0.00% | 0.0% |
| Q2 2015 | $184,000 | +65.8% | 1,800 | 0.0% | 0.00% | – |
| Q1 2015 | $111,000 | +40.5% | 1,800 | 0.0% | 0.00% | – |
| Q4 2014 | $79,000 | – | 1,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |